Abstract – A targeted, stimuli-responsive, polymeric drug delivery vehicle has been developed to help alleviate the severe side-effects caused by narrow therapeutic window drugs. Doxorubicin, a commonly used chemotherapeutic agent has been conjugated to dextran by two different techniques. In the first method, doxorubicin and hepatocyte-targeting galactosamine were attached to dextran through amine bonds. Conjugation efficiency based on the amount loaded of each reactant varied from 1 % to 50 % for doxorubicin and from 2 % to 20 % for galactosamine, depending on various synthesis parameters. For the second conjugate, doxorubicin was attached to dextran through an acid-labile hydrazide bond. Fluorescence quenching indicated that all our conj...
In an attempt to explore the potential of dendritic systems for the development of effective antican...
In an attempt to develop the hypoxia-responsive nanoparticles for cancer therapy, a polymer conjugat...
ide (HPMA) copolymer-based doxorubicin (DOX) conjugates de-signed for passive tumor targeting was st...
A targeted, stimuli-responsive, polymeric drug delivery vehicle has been developed to help alleviate...
Reduction-responsive nano-carriers have been confirmed to be promising for intracellular drug delive...
We previously showed that conjugating doxorubicin to very large 70-500 kDa dextran decreased its rem...
Most chemotherapeutic agents are nonspecific distribution and cause systemic toxicities. Polysacchar...
[[abstract]]©2002 Brill - Three kinds of polymeric adriamycin (ADR) conjugates of dextran were synth...
Intercalation of drugs into assembled DNA systems offers versatile new mechanisms for controlled dru...
ABSTRACT: Poly(PEG-Lys) is a new, water soluble poly(ether urethane) that has shown promise as an in...
A major challenge of combinatorial therapy is the unification of the pharmacokinetics and cellular u...
cancer activity following targeting of a polymer bear-ing doxorubicin with galactosamine (PK2) to th...
Amphiphilic ethylenediamine (EDA)-functionalized V-shape and star copolymers with centrally placed m...
New conjugation chemistry for polysaccharides, exemplified by dextran, was developed to enable the a...
Nanoparticles with active-targeting and stimuli-responsive behavior are a promising class of enginee...
In an attempt to explore the potential of dendritic systems for the development of effective antican...
In an attempt to develop the hypoxia-responsive nanoparticles for cancer therapy, a polymer conjugat...
ide (HPMA) copolymer-based doxorubicin (DOX) conjugates de-signed for passive tumor targeting was st...
A targeted, stimuli-responsive, polymeric drug delivery vehicle has been developed to help alleviate...
Reduction-responsive nano-carriers have been confirmed to be promising for intracellular drug delive...
We previously showed that conjugating doxorubicin to very large 70-500 kDa dextran decreased its rem...
Most chemotherapeutic agents are nonspecific distribution and cause systemic toxicities. Polysacchar...
[[abstract]]©2002 Brill - Three kinds of polymeric adriamycin (ADR) conjugates of dextran were synth...
Intercalation of drugs into assembled DNA systems offers versatile new mechanisms for controlled dru...
ABSTRACT: Poly(PEG-Lys) is a new, water soluble poly(ether urethane) that has shown promise as an in...
A major challenge of combinatorial therapy is the unification of the pharmacokinetics and cellular u...
cancer activity following targeting of a polymer bear-ing doxorubicin with galactosamine (PK2) to th...
Amphiphilic ethylenediamine (EDA)-functionalized V-shape and star copolymers with centrally placed m...
New conjugation chemistry for polysaccharides, exemplified by dextran, was developed to enable the a...
Nanoparticles with active-targeting and stimuli-responsive behavior are a promising class of enginee...
In an attempt to explore the potential of dendritic systems for the development of effective antican...
In an attempt to develop the hypoxia-responsive nanoparticles for cancer therapy, a polymer conjugat...
ide (HPMA) copolymer-based doxorubicin (DOX) conjugates de-signed for passive tumor targeting was st...